Try our Advanced Search for more refined results

February 28, 2017

Momenta Pharmaceuticals, Inc. v. Bristol-Myers Squibb Company

Track this case

Case Number:

17-1694

Court:

Appellate - Federal Circuit

Nature of Suit:

- 

Companies

Sectors & Industries:

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. February 07, 2019

    Fed. Circ. Kills Patent Fight After Momenta Ditches Biosimilar

    Momenta Pharmaceuticals Inc. can't challenge a patent for Bristol-Myers Squibb Co.'s rheumatoid arthritis drug Orencia because Momenta has stopped developing a biosimilar version of the blockbuster product, the Federal Circuit ruled Thursday.

2 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!